. Author manuscript; available in PMC: 2012 Mar 1.

Published in final edited form as: Am J Obstet Gynecol. 2010 Dec 17;204(3):211.e1–211.e6. doi: 10.1016/j.ajog.2010.10.898

Table 3.

Short term recurrence rates, as defined by Nugent criteria, after completion of successful therapy by randomized treatment group (N (%))

Nugent Score	Metronidazole	Tinidazole 1 gm	Tinidazole 500mg	P value
	500mg BID	BID	500mg BID
1 month follow-up
≥7	34/102 (33.3)	20/89 (22.5)	29/96 (30.2)	0.24
<7	68/102 (66.7)	69/89 (77.5)	67/96 (69.8)
2 month follow-up
≥7	19/56 (33.9)	12/59 (20.3%)	22/55 (40.0)	0.07
<7	4/56 (66.1)	6/59 (79.7%)	3/55 (60.0)

Note. Women defined as failures at 14 day visit not included in the analysis